Our dedicated team works closely with clients through all stages of the drug discovery and development process to select the best approach from Non-Clinical studies to Clinical trials.


In vitro assays


Lead compounds can be characterized in various functional cell-based assays such as:

- Proliferation assays (WST-1),

- Clonogenicity (colony forming),

- Cell Migration assays 

- Antibody Dependant Cytotoxicity (ADCC)






In vivo studies


Biotrial’s portfolio of preclinical services is completed by in vivo testing services including both subcutaneous and orthotopic tumor models (both xenograft and syngenic models) with in vivo and ex vivo bioluminescence analysis.


Standard in vivo models are available for the following cell lines:

Breast Cancer: MDA-MB-231, BT-549, Hs-549, MCF-7

Colon Cancer: HT-29, HCT-15, HCT-116

Melanoma: A375, B16F10

Ovarian Cancer: SKOV-3

Glioblastoma: U87MG, U87MG-Luc, U-251

Prostate Cancer: MDA-PCA2b, PC-3

Kidney Cancer: 786-O

Lung cancer: A549, Calu-6, NCI-H460


in vivo efficacy study using Temozolomide in a orthotopic U87MG xenograft model


Cell lines are implanted either subcutaneously or orthotopically into Nude mice. Tumour growth is measured manually with a caliper or with bioluminescence when available. Clinical monitoring consists of body weight, clinical observation battery for mortality and morbidity.

Different types of analysis could be performed such as blood sampling, collection of tumours at the end of the experiment for histology and IHC.

In addition, our close collaboration with the University Hospital Complex in Rennes gives us privileged access to various tumor collections and provide our clients with tailored models and solutions. Our R&D department is actively working on the development of unique tumour models: we propose unique tumour stem-like cells in Glioblastoma and Triple Negative Breast Cancer which more closely mimic original patient biology as well as various access to tumour samples. We can also propose to test your compounds in an organotypic ex vivo assay using fresh human kidney tumour samples.



Imaging of small animals


  • DCE-MRI: IRM 4.7T BIOSPEC AVANCE 47/40 USR (Bruker-BioSpin) with dedicated mice (gradients 950mT/m, 35 mm diameter) or rat (400mT/m 72mm diameter) kits « Whole body » coil


  • Imaging Systems for Fluorescence and Luminescence: PHOTONIMAGER OPTIMA for non-invasive, localization and quantification of dynamic optical signal - Bioluminescence or Fluorescence – from rodents. The imager is also equipped with an X-RAY module for accurate anatomic localization of optical signals and a TomoFluo module for 3D quantification of fluorescence signals in vivo.







 Combination Studies

  • Irradiator Faxitron CellRAd (10 kV - 150 kV): Irradiation could be performed in whole animal or as localized irradiation to target the primary tumour site. It also can be used to irradiate cells for projects in vitro.


In vivo efficacy study using irradiation doses in a subcutaneous PC-3 xenograft model
Click to enlarge

Histology & Immunohistochemistry (tumor samples obtained from patient or rodents)

  • Laser Capture Microdissection (Veritas; Arcturus), Tissue Micro Array (TMA)
  • Slide Scanner Technology, (Nanozoomer NDP, Hamamatsu)
  • Vibrating Microtome (Leica, V1200) fortechniques such as histology, organotypic slice culture

Translational Approach


Biotrial is actively investing in R&D projects to develop innovative and unique models.

We have established a Translational Group dedicated to developing unique and innovative models in the field of Oncology. If you are interested in learning more about our current model developments, please visit our Translational Groups page.